JW Jungwoo, 2Q Sales 183.5 Billion KRW... Operating Profit Up 120%

JW Pharmaceutical's sales and operating profit in the second quarter experienced rapid growth, achieving the highest-ever performance for the second quarter.

JW Pharmaceutical's New Headquarters in Gwacheon-si, Gyeonggi Province [Photo by JW Pharmaceutical]

On the 9th, JW Pharmaceutical announced its preliminary operating results, reporting second-quarter sales of 183.48 billion KRW and operating profit of 22.71 billion KRW based on separate financial statements. Compared to the same period last year, sales increased by 12.6%, and operating profit surged by an impressive 120%. The company explained, "Operating profit grew significantly thanks to the sales growth of original pharmaceuticals with secured product and cost competitiveness." Net profit also rose dramatically by 736% to 16.95 billion KRW.

The cumulative results for the first half of this year showed sales of 354.851 billion KRW and operating profit of 44.215 billion KRW, representing increases of 11.9% and 81.0%, respectively, compared to the same period last year.

The company stated that both the ethical drugs (ETC) and over-the-counter (OTC) business sectors grew, maintaining a continuous upward trend in sales. In the second quarter of this year, ETC sales reached 143.9 billion KRW, a 11.3% increase from 129.3 billion KRW in the same period last year. By product, the improved new drug for dyslipidemia combination ‘Rivaroget’ grew by 146.4% year-on-year to 17 billion KRW, and the Rivaroget product line including the statin monotherapy ‘Rivaro’ recorded sales of 37.3 billion KRW, up 40.2%. Additionally, the hemophilia treatment ‘Hemlibra’ achieved sales of 4.4 billion KRW, soaring 214.3% since insurance coverage expansion began in May.

The infusion solution segment grew by 5.6% year-on-year to 46.9 billion KRW. The high-value-added total parenteral nutrition solution ‘Winnerf’ led the growth in this segment with a 24.5% increase, reaching 18.3 billion KRW in sales.

The OTC segment recorded sales of 14.6 billion KRW, up 8.9% from the same period last year. The eye care brand ‘Friends’ achieved 4.1 billion KRW (20.6%↑), the wound care band ‘HiMom’ 2.5 billion KRW (8.7%↑), and the sterile saline solution ‘Cleancl’ 2.3 billion KRW (27.8%↑). The business-to-business (B2B) segment also grew by 7.9% to 9.6 billion KRW, driven by increased contract manufacturing organization (CMO) sales.

A JW Pharmaceutical representative said, “The Rivaroget product line, including Rivaro, continues to show strong growth as it gains market recognition, maintaining solid growth centered on key original ETC products.” He added, “With the addition of Hemlibra, whose sales are rapidly increasing due to expanded insurance coverage, the outlook for the second half of the year is also bright.”

This content was produced with the assistance of AI translation services.